Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The miniaturized Micra AV and Micra VR* transcatheter pacing systems (TPS) are the world's smallest pacemakers1 for bradyarrhythmia management, delivered percutaneously via a minimally invasive approach without the use of leads.
Download BrochureMeet Micra AV
Now with AV synchrony,2 allowing more of your patients to benefit from leadless pacing.
Parameter |
Micra AV5 |
Micra VR6 |
---|---|---|
Pacing Mode |
VVI, VVIR, VOO, OVO, VDD, VDI, ODO, OFF |
VVI, VVIR, VOO, OVO, OFF |
Mass |
1.75 g |
1.75 g |
Volume |
0.8 cc |
0.8 cc |
Electrode Spacing |
18 mm |
18 mm |
Battery Longevity |
8–13 years†5,7 |
12 years‡8 |
Accelerometer-based Mechanical Atrial Sensing |
Yes |
N/A |
Accelerometer-based Rate Response |
Yes |
Yes |
MRI SureScan™ |
1.5T & 3T |
1.5T & 3T |
CareLink™ Remote Monitoring |
Yes |
Yes |
The MARVEL 2 trial is a multicenter, pivotal IDE study in which the MARVEL 2 algorithm was downloaded into existing Micra VR devices in order to provide AV synchronous pacing.
Real-world experience reinforces safety and long-term performance of Micra VR.
Micra VR Design Journey Video - (02:45)
See how Micra is implanted - (03:33)
Micra VR 92-year-old Patient Video - (01:41)
How Micra VR allows singer Stephen to live his life without worry - (02:28)
Access interactive courses, videos, and educational resources to extend your learning on Micra.
Visit Medtronic AcademyThe single chamber Micra™ Transcatheter Pacing System is being described herein as Micra™ VR in order to distinguish it from the dual chamber (VDD) Micra™ AV product. When information in this document relates to both Micra AV and VR, “Micra™ Transcatheter Pacing Systems” is used to represent the portfolio of devices.
Use conditions include:
8 years = 100% VDD pacing, 60 bpm, pacing threshold 1.5 V, impedance 500 Ω, pulse width 0.24 ms.
13 years = 15% VDD pacing, 70 bpm, pacing threshold 1.5 V, impedance 600 Ω, pulse width 0.24 ms.
Use conditions included: median pacing 53.5%, median pacing threshold 0.50 V, median impedance 543 Ω; 89% of patients with > 10-year projected longevity; 99% of patients with > 5-year longevity.12
Nippoldt D, Whiting J. Micra Transcatheter Pacing System Device Volume Characterization Comparison. November 2014. Medtronic data on file.
Medtronic Micra™ AV MC1AVR1 Reference Manual. January 2020.
Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. May 2012;9(5):728-735.
Williams E, Whiting J. Micra Transcatheter Pacing System Size Comparison. November 2014. Medtronic data on file.
Medtronic Micra™ AV MC1AVR1 Device Manual. January 2020.
Medtronic Micra™ MC1VR01 Clinician Manual. October 2016.
Pender J, Whiting J. Micra AV Battery Longevity. January 2020. Medtronic data on file.
Duray GZ, Ritter P, El-Chami M et al. Long-term performance of a transcatheter pacing system: 12-Month Results from the Micra Transcatheter Pacing Study. Heart Rhythm. May 2017;14(5):702-709.
Reynolds D, Duray GZ, Omar R, et al. A Leadless Intracardiac Transcatheter Pacing System. N Engl J Med. February 11, 2016;374(6):533-541.
El-Chami MF, Al-Samadi F, Clementy N, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Heart Rhythm. December 2018;15(12):1800-1807.
Steinwender C, Khelae SK, Garweg C, et al. Atrioventricular synchronous pacing using a leadless ventricular pacemaker: Results from the MARVEL 2 Study. JACC Clin Electrophysiol. 2020;6(1):94-106.
Ritter P, et al. Long-Term Performance of a Transcatheter Pacing System: 12-month results from the Micra Global Clinical Trial. LBCT presentation at ESC 2016; Rome, Italy.